Table 4:
Best tumour response per dose in all enrolled patients
Number of patients | Complete response plus partial response | Disease control (complete response plus partial response plus stable disease) | |
---|---|---|---|
200 mg/day | 3 | 1 (33%) | 1 (33%) |
400 mg/day | 6 | 1 (17%) | 4 (67%) |
600 mg/day | 7 | 2 (29%) | 6 (86%) |
800 mg/day | 15 | 7 (47%) | 14 (93%) |
Data are n (%) of patients who achieved a response with differing doses of pazopanib. All patients received pazopanib at the indicated doses plus weekly cetuximab.